ANDA 72164, held by Watson Labs. Maprotiline Hydrochloride.
As of Nov 16, 2026, ANDA 72164 (Maprotiline Hydrochloride), held by Watson Labs, was first approved by FDA on Jun 1, 1988, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Maprotiline Hydrochloride75MG · tablet;oral | Maprotiline Hydrochloride | Discontinued |
| Jul 17, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 7, 2002 | Supplement 8Manufacturing | Approved | None posted |
| Nov 10, 1999 | Supplement 7Manufacturing | Approved | None posted |
| Aug 26, 1998 | Supplement 6Labeling | Approved | None posted |
| Jun 4, 1992 | Supplement 5Labeling | Approved | None posted |
| May 20, 1992 | Supplement 4Labeling | Approved | None posted |
| Nov 29, 1990 | Supplement 3Labeling | Approved | None posted |
| May 15, 1989 | Supplement 2Manufacturing | Approved | None posted |
| Jun 1, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters